Effect of Gut Microbiome on Chemotherapy Response in Patients with Colorectal Cancer: a Prospective Cohort Study
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i2.2320
Abstract
This review aims to explore the emerging role of the tumor microbiome in tumor development and treatment, particularly in the impact of chemotherapy responses in patients with colorectal cancer. We discussed that the gut microbiome may influence the occurrence and progression of colorectal cancer by participating in the occurrence of colorectal cancer and regulating the host's immune response and metabolic status, as well as the effect of chemotherapy by influencing drug metabolism, regulating immune response, or participating in the side effects of chemotherapy. Research suggests that tweaking the gut microbiome may help improve the efficacy of chemotherapy. This may involve strategies such as the use of probiotics, prebiotics, or fecal microbial transplants. However, there are many challenges to the application of these strategies, such as the fact that we do not yet know which microbes are beneficial and which are harmful, and that the same strategy may have different effects on different people. Future research may therefore focus on a deeper understanding of how the gut microbiome influences tumor biological behavior and how this knowledge can be used to improve treatment outcomes for patients with colorectal cancer.
Keywords
intestinal microbiome, colorectal cancer, chemotherapy, prospective cohort study
Full Text
PDF - Viewed/Downloaded: 3 TimesReferences
[1] Meng, Yang, Xiaoqi, Zheng, Jiajun, Fan et al. Antibiotic-Induced Gut Microbiota Dysbiosis Modulates Host Transcriptome and m(6)A Epitranscriptome via Bile Acid Metabolism[J]. Adv Sci (Weinh), 2024, 0: 0.
[2] Cynthia L, Hsu, Bernd, Schnabl, The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol, 2023, 21: 0.
[3] Zehua, Li, Weixi, Xiong, Zhu, Liang et al. Critical role of the gut microbiota in immune responses and cancer immunotherapy[J]. J Hematol Oncol, 2024, 17: 0.
[4] Elizabeth M, Park, Manoj, Chelvanambi, Neal, Bhutiani et al. Targeting the gut and tumor microbiota in cancer[J]. Nat Med, 2022, 28: 0.
[5] Beth A, Helmink, M A Wadud, Khan, Amanda, Hermann et al. The microbiome, cancer, and cancer therapy[J]. Nat Med, 2019, 25: 0.
[6] Sun Ying, Ma Jin, Gu Wei, et al. The significance of colorectal cancer screening in the early diagnosis of colorectal tumors [J]. Gastroenterology, 2012, 27(03): 173-176. (in Chinese)
[7] Dominguez-Bello Maria G, Costello Elizabeth K, Contreras Monica et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns[J]. Proc Natl Acad Sci U S A, 2010, 107: 11971-5.
[8] de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. [J]. Gut. 2022;71(5):1020-1032.
[9] Huang Libin, Huang Qiushi, Yang Lie. Epidemiological characteristics and prevention of colorectal cancer in the world and China: An interpretation of the 2022 Global Cancer Statistics Report [J/OL]. Outside China's basic and clinical magazine: 1-8 [2024-05-16]. http://kns. cnki. net/kcms/detail/ 51. 1505. R. 20240426. 1611. 002. HTML.
[10] Lu Jiaxuan, He Jiawen, Han Bing, et al. Wang Ruiping's experience in differentiation and treatment of colorectal cancer [J]. Hubei Journal of Traditional Chinese Medicine, 2019, 46(05):31-34.
[11] Xue Siqi, He Jing, Tang Yong. Research progress in treatment of colon cancer [J]. Chinese Medical Sciences, 2022, 12(09):58-61.
[12] Wong Sunny H, Yu Jun, Gut microbiota in colorectal cancer: mechanisms of action and clinical applications[J]. Nat Rev Gastroenterol Hepatol, 2019, 16: 690-704.
[13] Chen Weiguang, Liu Fanlong, Ling Zongxin et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer[J]. PLoS One, 2012, 7: e39743.
[14] Saffarian Azadeh, Mulet Céline, Regnault Béatrice et al. Crypt- and Mucosa-Associated Core Microbiotas in Humans and Their Alteration in Colon Cancer Patients[J]. mBio, 2019, 10: undefined.
[15] Zeller Georg, Tap Julien, Voigt Anita Y et al. Potential of fecal microbiota for early-stage detection of colorectal cancer[J]. Mol Syst Biol, 2014, 10: 766.
[16] Kostic Aleksandar D, Chun Eunyoung, Robertson Lauren et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microbe, 2013, 14: 207-15.
[17] Song Mingyang, Chan Andrew T, Sun Jun, Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer[J]. Gastroenterology, 2020, 158: 322-340.
[18] Wang Ji, Chen Wei-Dong, Wang Yan-Dong, The Relationship Between Gut Microbiota and Inflammatory Diseases: The Role of Macrophages[J]. Front Microbiol, 2020, 11: 1065.
[19] Lavelle Aonghus, Sokol Harry, Gut microbiota-derived metabolites as key actors in inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17: 223-237.
[20] Huycke Mark M, Moore Danny R, In vivo production of hydroxyl radical by Enterococcus faecalis colonizing the intestinal tract using aromatic hydroxylation[J]. Free Radic Biol Med, 2002, 33: 818-26.
[21] Evans Mark D, Dizdaroglu Miral, Cooke Marcus S, Oxidative DNA damage and disease: induction, repair and significance[J]. Mutat Res, 2004, 567: 1-61.
[22] Castellarin Mauro, Warren René L, Freeman J Douglas et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma[J]. Genome Res, 2012, 22: 299-306.
[23] Koliarakis Ioannis, Messaritakis Ippokratis, Nikolouzakis Taxiarchis Konstantinos et al. Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer[J]. Int J Mol Sci, 2019, 20: undefined.
[24] Wu Jiao, Li Qing, Fu Xiangsheng, Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity[J]. Transl Oncol, 2019, 12: 846-851.
[25] Gur Chamutal, Ibrahim Yara, Isaacson Batya et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack[J]. Immunity, 2015, 42: 344-355.
[26] Rubinstein Mara Roxana, Wang Xiaowei, Liu Wendy et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin[J]. Cell Host Microbe, 2013, 14: 195-206.
[27] Iida Noriho, Dzutsev Amiran, Stewart C Andrew et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J]. Science, 2013, 342: 967-70.
[28] Kim Jaeho, Lee Heung Kyu, Potential Role of the Gut Microbiome In Colorectal Cancer Progression[J]. Front Immunol, 2021, 12: 807648.
[29] Badgeley Aja, Anwar Hina, Modi Karan et al. Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875: 188494.
[30] Spanogiannopoulos Peter, Bess Elizabeth N, Carmody Rachel N et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism[J]. Nat Rev Microbiol, 2016, 14: 273-87.
[31] Viaud Sophie, Saccheri Fabiana, Mignot Grégoire et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science, 2013, 342: 971-6.
[32] Stein Alexander, Voigt Wieland, Jordan Karin, Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management[J]. Ther Adv Med Oncol, 2010, 2: 51-63.
[33] Mani Sridhar, Boelsterli Urs A, Redinbo Matthew R, Understanding and modulating mammalian-microbial communication for improved human health[J]. Annu Rev Pharmacol Toxicol, 2014, 54: 559-80.
[34] Pouncey Anna Louise, Scott Alasdair James, Alexander James Leslie et al. Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment[J]. Ecancermedicalscience, 2018, 12: 868.
[35] Perez-Chanona Ernesto, Trinchieri Giorgio, The role of microbiota in cancer therapy[J]. Curr Opin Immunol, 2016, 39: 75-81.
[36] Frank Magdalena, Hennenberg Eva Maria, Eyking Annette et al. TLR signaling modulates side effects of anticancer therapy in the small intestine[J]. J Immunol, 2015, 194: 1983-95.
[37] Mills John P, Rao Krishna, Young Vincent B, Probiotics for prevention of Clostridium difficile infection[J]. Curr Opin Gastroenterol, 2018, 34: 3-10.
[38] Piewngam Pipat, Zheng Yue, Nguyen Thuan H et al. Pathogen elimination by probiotic Bacillus via signalling interference[J]. Nature, 2018, 562: 532-537.
[39] Fong Winnie, Li Qing, Yu Jun, Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer[J]. Oncogene, 2020, 39: 4925-4943.
[40] Gibson G R, Roberfroid M B, Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics[J]. J Nutr, 1995, 125: 1401-12.
[41] Hibberd Ashley A, Lyra Anna, Ouwehand Arthur C et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention[J]. BMJ Open Gastroenterol, 2017, 4: e000145.
[42] Rosshart Stephan P, Vassallo Brian G, Angeletti Davide et al. Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance[J]. Cell, 2017, 171: 1015-1028. e13.
[43] Wilson Ian D, Nicholson Jeremy K, Gut microbiome interactions with drug metabolism, efficacy, and toxicity[J]. Transl Res, 2017, 179: 204-222.
[2] Cynthia L, Hsu, Bernd, Schnabl, The gut-liver axis and gut microbiota in health and liver disease[J]. Nat Rev Microbiol, 2023, 21: 0.
[3] Zehua, Li, Weixi, Xiong, Zhu, Liang et al. Critical role of the gut microbiota in immune responses and cancer immunotherapy[J]. J Hematol Oncol, 2024, 17: 0.
[4] Elizabeth M, Park, Manoj, Chelvanambi, Neal, Bhutiani et al. Targeting the gut and tumor microbiota in cancer[J]. Nat Med, 2022, 28: 0.
[5] Beth A, Helmink, M A Wadud, Khan, Amanda, Hermann et al. The microbiome, cancer, and cancer therapy[J]. Nat Med, 2019, 25: 0.
[6] Sun Ying, Ma Jin, Gu Wei, et al. The significance of colorectal cancer screening in the early diagnosis of colorectal tumors [J]. Gastroenterology, 2012, 27(03): 173-176. (in Chinese)
[7] Dominguez-Bello Maria G, Costello Elizabeth K, Contreras Monica et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns[J]. Proc Natl Acad Sci U S A, 2010, 107: 11971-5.
[8] de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. [J]. Gut. 2022;71(5):1020-1032.
[9] Huang Libin, Huang Qiushi, Yang Lie. Epidemiological characteristics and prevention of colorectal cancer in the world and China: An interpretation of the 2022 Global Cancer Statistics Report [J/OL]. Outside China's basic and clinical magazine: 1-8 [2024-05-16]. http://kns. cnki. net/kcms/detail/ 51. 1505. R. 20240426. 1611. 002. HTML.
[10] Lu Jiaxuan, He Jiawen, Han Bing, et al. Wang Ruiping's experience in differentiation and treatment of colorectal cancer [J]. Hubei Journal of Traditional Chinese Medicine, 2019, 46(05):31-34.
[11] Xue Siqi, He Jing, Tang Yong. Research progress in treatment of colon cancer [J]. Chinese Medical Sciences, 2022, 12(09):58-61.
[12] Wong Sunny H, Yu Jun, Gut microbiota in colorectal cancer: mechanisms of action and clinical applications[J]. Nat Rev Gastroenterol Hepatol, 2019, 16: 690-704.
[13] Chen Weiguang, Liu Fanlong, Ling Zongxin et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer[J]. PLoS One, 2012, 7: e39743.
[14] Saffarian Azadeh, Mulet Céline, Regnault Béatrice et al. Crypt- and Mucosa-Associated Core Microbiotas in Humans and Their Alteration in Colon Cancer Patients[J]. mBio, 2019, 10: undefined.
[15] Zeller Georg, Tap Julien, Voigt Anita Y et al. Potential of fecal microbiota for early-stage detection of colorectal cancer[J]. Mol Syst Biol, 2014, 10: 766.
[16] Kostic Aleksandar D, Chun Eunyoung, Robertson Lauren et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microbe, 2013, 14: 207-15.
[17] Song Mingyang, Chan Andrew T, Sun Jun, Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer[J]. Gastroenterology, 2020, 158: 322-340.
[18] Wang Ji, Chen Wei-Dong, Wang Yan-Dong, The Relationship Between Gut Microbiota and Inflammatory Diseases: The Role of Macrophages[J]. Front Microbiol, 2020, 11: 1065.
[19] Lavelle Aonghus, Sokol Harry, Gut microbiota-derived metabolites as key actors in inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17: 223-237.
[20] Huycke Mark M, Moore Danny R, In vivo production of hydroxyl radical by Enterococcus faecalis colonizing the intestinal tract using aromatic hydroxylation[J]. Free Radic Biol Med, 2002, 33: 818-26.
[21] Evans Mark D, Dizdaroglu Miral, Cooke Marcus S, Oxidative DNA damage and disease: induction, repair and significance[J]. Mutat Res, 2004, 567: 1-61.
[22] Castellarin Mauro, Warren René L, Freeman J Douglas et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma[J]. Genome Res, 2012, 22: 299-306.
[23] Koliarakis Ioannis, Messaritakis Ippokratis, Nikolouzakis Taxiarchis Konstantinos et al. Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer[J]. Int J Mol Sci, 2019, 20: undefined.
[24] Wu Jiao, Li Qing, Fu Xiangsheng, Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity[J]. Transl Oncol, 2019, 12: 846-851.
[25] Gur Chamutal, Ibrahim Yara, Isaacson Batya et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack[J]. Immunity, 2015, 42: 344-355.
[26] Rubinstein Mara Roxana, Wang Xiaowei, Liu Wendy et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin[J]. Cell Host Microbe, 2013, 14: 195-206.
[27] Iida Noriho, Dzutsev Amiran, Stewart C Andrew et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J]. Science, 2013, 342: 967-70.
[28] Kim Jaeho, Lee Heung Kyu, Potential Role of the Gut Microbiome In Colorectal Cancer Progression[J]. Front Immunol, 2021, 12: 807648.
[29] Badgeley Aja, Anwar Hina, Modi Karan et al. Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875: 188494.
[30] Spanogiannopoulos Peter, Bess Elizabeth N, Carmody Rachel N et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism[J]. Nat Rev Microbiol, 2016, 14: 273-87.
[31] Viaud Sophie, Saccheri Fabiana, Mignot Grégoire et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science, 2013, 342: 971-6.
[32] Stein Alexander, Voigt Wieland, Jordan Karin, Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management[J]. Ther Adv Med Oncol, 2010, 2: 51-63.
[33] Mani Sridhar, Boelsterli Urs A, Redinbo Matthew R, Understanding and modulating mammalian-microbial communication for improved human health[J]. Annu Rev Pharmacol Toxicol, 2014, 54: 559-80.
[34] Pouncey Anna Louise, Scott Alasdair James, Alexander James Leslie et al. Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment[J]. Ecancermedicalscience, 2018, 12: 868.
[35] Perez-Chanona Ernesto, Trinchieri Giorgio, The role of microbiota in cancer therapy[J]. Curr Opin Immunol, 2016, 39: 75-81.
[36] Frank Magdalena, Hennenberg Eva Maria, Eyking Annette et al. TLR signaling modulates side effects of anticancer therapy in the small intestine[J]. J Immunol, 2015, 194: 1983-95.
[37] Mills John P, Rao Krishna, Young Vincent B, Probiotics for prevention of Clostridium difficile infection[J]. Curr Opin Gastroenterol, 2018, 34: 3-10.
[38] Piewngam Pipat, Zheng Yue, Nguyen Thuan H et al. Pathogen elimination by probiotic Bacillus via signalling interference[J]. Nature, 2018, 562: 532-537.
[39] Fong Winnie, Li Qing, Yu Jun, Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer[J]. Oncogene, 2020, 39: 4925-4943.
[40] Gibson G R, Roberfroid M B, Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics[J]. J Nutr, 1995, 125: 1401-12.
[41] Hibberd Ashley A, Lyra Anna, Ouwehand Arthur C et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention[J]. BMJ Open Gastroenterol, 2017, 4: e000145.
[42] Rosshart Stephan P, Vassallo Brian G, Angeletti Davide et al. Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance[J]. Cell, 2017, 171: 1015-1028. e13.
[43] Wilson Ian D, Nicholson Jeremy K, Gut microbiome interactions with drug metabolism, efficacy, and toxicity[J]. Transl Res, 2017, 179: 204-222.
Copyright © 2024 Xuying Ma, Ying Wang, Shuang Zheng
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License